Medtronic has launched new MR-Conditional pacing system for use with MRI scanners in the US, following the approval from the US Food and Drug Administration (FDA).
The Advisa DR MRI SureScan pacing system, which includes an Advisa MRI device and two CapSureFix MRI SureScan leads, allows physicians to perform MRI scanning in patients with implanted cardiac devices such as pacemakers.
During the company's Advisa MRI clinical trial, none out of 156 patients scanned showed any MRI-related complications.
The pacing system, which offers complete automaticity with Ventricular and Atrial Capture Management, eliminates manual threshold checks and extends longevity of the device by up to one year, claims the company.
The system features diagnostics tools such as the Cardiac Compass Report, and AF management, which facilitate physicians in the early detection and treatment of atrial fibrillation, and high upper tracking rate to provide pacing support at higher heart rates for active and younger patients.
In addition, the company said diagnostic device and comprehensive arrhythmia data can be transmitted to a physician's clinic by remote monitoring of the patient via Medtronic's CareLink Network.
